Indivior (NASDAQ:INDV) Shares Gap Down – Should You Sell?

Indivior PLC (NASDAQ:INDV) gapped down before the market opened on Tuesday . The stock had previously closed at $9.52, but opened at $9.23. Indivior shares last traded at $9.45, with a volume of 114,520 shares.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. RODMAN&RENSHAW upgraded Indivior to a “strong-buy” rating in a research note on Tuesday, January 28th. Piper Sandler decreased their price objective on shares of Indivior from $16.00 to $13.00 and set an “overweight” rating on the stock in a report on Thursday, March 6th. Finally, Rodman & Renshaw began coverage on shares of Indivior in a research note on Tuesday, January 28th. They set a “buy” rating and a $16.00 target price for the company.

Indivior Stock Performance

The company has a fifty day moving average of $10.75 and a two-hundred day moving average of $10.54. The firm has a market capitalization of $1.35 billion, a price-to-earnings ratio of -27.89 and a beta of 0.82.

Indivior (NASDAQ:INDV) last announced its earnings results on Thursday, February 20th. The company reported $0.32 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.32. Indivior had a negative net margin of 3.96% and a negative return on equity of 241.73%. The company had revenue of $298.00 million during the quarter, compared to analysts’ expectations of $262.35 million. Equities analysts forecast that Indivior PLC will post 1.22 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in INDV. GF Fund Management CO. LTD. acquired a new stake in shares of Indivior in the fourth quarter valued at approximately $36,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Indivior in the fourth quarter worth $56,000. Lazard Asset Management LLC bought a new position in shares of Indivior in the fourth quarter worth $57,000. Stifel Financial Corp acquired a new position in Indivior in the third quarter valued at about $100,000. Finally, Melqart Asset Management UK Ltd bought a new stake in Indivior during the third quarter worth about $132,000. Institutional investors and hedge funds own 60.33% of the company’s stock.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.